231 related articles for article (PubMed ID: 25736055)
1. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
Nakashima S; Kobayashi S; Nagano H; Tomokuni A; Tomimaru Y; Asaoka T; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
Cancer Sci; 2015 May; 106(5):584-91. PubMed ID: 25736055
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Okumura Y; Noda T; Eguchi H; Sakamoto T; Iwagami Y; Yamada D; Asaoka T; Wada H; Kawamoto K; Gotoh K; Kobayashi S; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M
Ann Surg Oncol; 2018 Nov; 25(12):3728-3737. PubMed ID: 30105440
[TBL] [Abstract][Full Text] [Related]
3. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
4. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer.
Yamada D; Kobayashi S; Wada H; Kawamoto K; Marubashi S; Eguchi H; Ishii H; Nagano H; Doki Y; Mori M
Eur J Cancer; 2013 May; 49(7):1725-40. PubMed ID: 23298711
[TBL] [Abstract][Full Text] [Related]
5. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
[TBL] [Abstract][Full Text] [Related]
6. [Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway].
Xiong T; Wei H; Chen X; Xiao H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):312-6. PubMed ID: 24928009
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Ohtaka K; Kohya N; Sato K; Kitajima Y; Ide T; Mitsuno M; Miyazaki K
Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
[TBL] [Abstract][Full Text] [Related]
9. Exploring the link between MORF4L1 and risk of breast cancer.
Martrat G; Maxwell CM; Tominaga E; Porta-de-la-Riva M; Bonifaci N; Gómez-Baldó L; Bogliolo M; Lázaro C; Blanco I; Brunet J; Aguilar H; Fernández-Rodríguez J; Seal S; Renwick A; Rahman N; Kühl J; Neveling K; Schindler D; Ramírez MJ; Castellà M; Hernández G; ; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Lalloo F; Eeles R; Izatt L; Chu C; Davidson R; Ong KR; Cook J; Douglas F; Hodgson S; Brewer C; Morrison PJ; Porteous M; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Barile M; Viel A; Pasini B; Ottini L; Putignano AL; Savarese A; Bernard L; Radice P; Healey S; Spurdle A; Chen X; Beesley J; ; Rookus MA; Verhoef S; Tilanus-Linthorst MA; Vreeswijk MP; Asperen CJ; Bodmer D; Ausems MG; van Os TA; Blok MJ; Meijers-Heijboer HE; Hogervorst FB; ; Goldgar DE; Buys S; John EM; Miron A; Southey M; Daly MB; ; ; Harbst K; Borg A; Rantala J; Barbany-Bustinza G; Ehrencrona H; Stenmark-Askmalm M; Kaufman B; Laitman Y; Milgrom R; Friedman E; Domchek SM; Nathanson KL; Rebbeck TR; Johannsson OT; Couch FJ; Wang X; Fredericksen Z; Cuadras D; Moreno V; Pientka FK; Depping R; Caldés T; Osorio A; Benítez J; Bueren J; Heikkinen T; Nevanlinna H; Hamann U; Torres D; Caligo MA; Godwin AK; Imyanitov EN; Janavicius R; ; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Verny-Pierre C; Castera L; de Pauw A; Bignon YJ; Uhrhammer N; Peyrat JP; Vennin P; Ferrer SF; Collonge-Rame MA; Mortemousque I; McGuffog L; Chenevix-Trench G; Pereira-Smith OM; Antoniou AC; Cerón J; Tominaga K; Surrallés J; Pujana MA
Breast Cancer Res; 2011 Apr; 13(2):R40. PubMed ID: 21466675
[TBL] [Abstract][Full Text] [Related]
10. ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer.
Ueno G; Iwagami Y; Kobayashi S; Mitsufuji S; Yamada D; Tomimaru Y; Akita H; Asaoka T; Noda T; Gotoh K; Mori M; Doki Y; Eguchi H
Ann Surg Oncol; 2022 May; 29(5):2899-2909. PubMed ID: 34994902
[TBL] [Abstract][Full Text] [Related]
11. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication.
Shen X; Do H; Li Y; Chung WH; Tomasz M; de Winter JP; Xia B; Elledge SJ; Wang W; Li L
Mol Cell; 2009 Sep; 35(5):716-23. PubMed ID: 19748364
[TBL] [Abstract][Full Text] [Related]
12. Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer.
Gallmeier E; Hucl T; Calhoun ES; Cunningham SC; Bunz F; Brody JR; Kern SE
Cancer Biol Ther; 2007 May; 6(5):654-60. PubMed ID: 17387268
[TBL] [Abstract][Full Text] [Related]
13. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage.
Ohashi A; Zdzienicka MZ; Chen J; Couch FJ
J Biol Chem; 2005 Apr; 280(15):14877-83. PubMed ID: 15671039
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor.
Rego MA; Harney JA; Mauro M; Shen M; Howlett NG
Oncogene; 2012 Jan; 31(3):366-75. PubMed ID: 21685936
[TBL] [Abstract][Full Text] [Related]
15. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
Burkitt K; Ljungman M
Mol Cancer; 2008 Mar; 7():24. PubMed ID: 18325101
[TBL] [Abstract][Full Text] [Related]
16. Effect of midkine on gemcitabine resistance in biliary tract cancer.
Lu Y; Yan B; Guo H; Qiu L; Sun X; Wang X; Shi Q; Bao Y
Int J Mol Med; 2018 Apr; 41(4):2003-2011. PubMed ID: 29344648
[TBL] [Abstract][Full Text] [Related]
17. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
Chen P; Li J; Jiang HG; Lan T; Chen YC
Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
[TBL] [Abstract][Full Text] [Related]
18. Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.
Sakamoto Y; Yamagishi S; Okusaka T; Ojima H
Cells; 2019 Sep; 8(9):. PubMed ID: 31484399
[TBL] [Abstract][Full Text] [Related]
19. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2.
Godthelp BC; Wiegant WW; Waisfisz Q; Medhurst AL; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Feb; 594(1-2):39-48. PubMed ID: 16154163
[TBL] [Abstract][Full Text] [Related]
20. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
